VerisetTM hemostatic patch	TachoSil® (control)	Median time to hemostasis	17075	17306	The median time to hemostasis at the TBS was 1.5 min in patients treated with VerisetTM hemostatic patch and 3.0 min in patients treated with TachoSil® (p<0.0001), which was the minimum time based on instructions for use (Table 7).
VerisetTM hemostatic patch	TachoSil® (control)	Serious adverse events within 30 days post-surgery	1115	1302	. Serious adverse events within 30 days post-surgery were experienced by 12/44 (27.3%) patients treated with VerisetTM hemostatic patch and 10/45 (22.2%) in the TachoSil® group (p=0.6295)
VerisetTM hemostatic patch	TachoSil® (control)	difference in any surgical procedure or target bleeding site (TBS) characteristic	15456	15572	There was no significant difference between the two treatment groups in any surgical procedure or TBS characteristic
VerisetTM hemostatic patch	TachoSil® (control)	Median time to hemostasis	999	1116	Median time to hemostasis was 1.5 min with VerisetTM hemostatic patch, compared to 3.0 min with TachoSil® (p<0.0001).
VerisetTM hemostatic patch	TachoSil® (control)	Serious adverse events within 30 days post-surgery	1117	1303	Serious adverse events within 30 days post-surgery were experienced by 12/44 (27.3%) patients treated with VerisetTM hemostatic patch and 10/45 (22.2%) in the TachoSil® group (p=0.6295).
VerisetTM hemostatic patch	TachoSil® (control)	difference in any surgical procedure or target bleeding site (TBS) characteristic	15456	15573	There was no significant difference between the two treatment groups in any surgical procedure or TBS characteristic;
